1. Chakraborty D, Rangamani S, Kulothungan V,
Chaturvedi M, Stephen S, Das P,et all. Trends in
incidence of Ewing sarcoma of bone in India–
Evidence from the National Cancer Registry
Programme (1982–2011). Journal of bone oncology.
2018;12:49-53.
2. Whelan J, McTiernan A, Cooper N, Wong YK, Francis
M, Vernon S, Strauss SJ. Incidence and survival of
malignant bone sarcomas in England 1979–2007.
International Journal of Cancer. 2012;131(4):
E508-17.
3. Jawad MU, Cheung MC, Min ES, Schneiderbauer MM,
Koniaris LG, Scully SP. Ewing sarcoma demonstrates
racial disparities in incidence‐related and sexrelated
differences in outcome: an analysis of 1631
cases from the SEER database, 1973‐2005. Cancer:
Interdisciplinary International Journal of the
American Cancer Society. 2009;115(15):3526-36.
4. Rica C, Clara V, Island PE. Bone ( C40-41 ) - Both sexes
Percentage distribution of microscopically verified
cases by histological type Bone ( C40-41 ) - Both sexes
( contd ). Bone. X:40–2.
5. Worch J, Matthay KK, Neuhaus J, Goldsby R, DuBois
SG. Ethnic and racial differences in patients
with Ewing sarcoma. Cancer: Interdisciplinary
International Journal of the American Cancer Society.
2010;116(4):983-8.
6. Akbari A, Khayamzadeh M, Salmanian R, Motlagh AG,
Roshandel G, Nouri M, Akbari ME. National Cancer
Mortality-to-Incidence Ratio (MIR) in Iran (2005-
2014). International Journal of Cancer Management.
2019;12(6).
7. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L,
Parkin D, et al. International Classification of Diseases
for Oncology. 3th edition. Geneva, World Health
Organization; 2000. Available from: http://whqlibdoc.
who.int/publications/2000/9241545348_eng.pdf
8. Movahedi M, Haghighat S, Khayamzadeh M, Moradi
A, Ghanbari-Motlagh A, Mirzaei H, Esmail-Akbari M.
Survival rate of breast cancer based on geographical
variation in Iran, a national study. Iranian Red
Crescent Medical Journal. 2012;14(12):798..
9. Nafissi N, Khayamzadeh M, Zeinali Z, Mohammadi G,
Hosseini M, Akbari ME. Breast Cancer in Iran, from
Epidemiology, Clinicopathological and Biomarker
Feature. Advances in Bioresearch. 2017;8(2).
10. Solooki S, Vosoughi AR, Masoomi V. Epidemiology of
musculoskeletal tumors in Shiraz, south of Iran. Indian
journal of medical and paediatric oncology: official
journal of Indian Society of Medical & Paediatric
Oncology. 2011;32(4):187.
11. Seker MM, Kos T, Ozdemir N, Seker A, Aksoy S, Uncu D,
Zengin N. Treatment and outcomes of Ewing sarcoma
in Turkish adults: a single centre experience. Asian
Pac J Cancer Prev. 2014;15(1):327-30.
12. Bahgat G, Bahgat G. Saudi Arabia. Altern Energy
Middle East. 2013;33(4):78–92.
13. Qureshi A, Ahmad Z, Azam M, Idrees R. Epidemiological
data for common bone sarcomas. Asian Pac J Cancer
Prev. 2010;11(2):393-5.
14. Kutluk MT, Yalçın B, Akyüz C, Varan A, Ruacan Ş,
Büyükpamukçu M. Treatment results and prognostic
factors in Ewing sarcoma. Pediatric hematology and
oncology. 2004;21(7):597-610.
15. Obata H, Ueda T, Kawai A, Ishii T, Ozaki T, Abe S, Tanaka
K, Tsuchiya H, Matsumine A, Yabe H. Clinical outcome
of patients with Ewing sarcoma family of tumors of
bone in Japan: the Japanese Musculoskeletal Oncology
Group cooperative study. Cancer: Interdisciplinary
International Journal of the American Cancer Society.
2007;109(4):767-75.
16. Esiashvili N, Goodman M, Marcus RB. Changes in
incidence and survival of Ewing sarcoma patients over
the past 3 decades: Surveillance Epidemiology and
End Results data. Journal of pediatric hematology/
oncology. 2008;30(6):425-30.